Clinical Trial Update: Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of fasiglifam in type 2 diabetes patients with chronic kidney disease on hemodialysis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• fasiglifam (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease | Phase 3 | Status: WITHDRAWN